Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


J&J Q2 results

This article was originally published in The Gray Sheet

Executive Summary

Ethicon sales rose 8.2% to $1.13 billion in the second quarter, driven by sutures, biosurgicals and Mentor aesthetic devices, Johnson & Johnson reported July 20. The acquisition of Acclarent also contributed to growth, the firm noted. J&J bought the Balloon Sinuplasty developer for $785 million in December (1"The Gray Sheet" Dec. 21, 2009). Advanced sterilization and Harmonic ultrasonic devices helped grow Ethicon Endo-Surgery revenues 6.6% to $1.2 billion. The Cordis division continued to struggle, with sales dropping 2.8% to $655 million. Medical devices and diagnostics sales of $6.1 billion were up 3.5% overall

You may also be interested in...

Ethicon Opens Up To Chronic Sinusitis Market With $785 Mil. Acclarent Buy

Johnson & Johnson/Ethicon will use its $785 million acquisition of Acclarent, developer of the Balloon Sinuplasty system for chronic sinusitis, as a platform for growth in the ear, nose and throat business

Abbott Launches Five-Minute POC Rapid COVID-19 Test

Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.

In A Bizarre Move, Trump Orders GM To Make Ventilators – Even Though The Auto Giant Already Is

President Trump on 27 March finally pulled the trigger on using his powers under the Defense Production Act, forcing General Motors Co. to manufacture medical ventilators. The only thing is, GM is already doing that.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts